The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVII.f

Tuberculosis, miliary

Publications

Koschny R, Junghanss T, Mischnik A, Karner M, Kreuter M, Roth W, Stremmel W, Merle U

Development of miliary tuberculosis under infliximab in a patient with spondyloarthritis and suspected Crohn's disease.

Zeitschrift fur Gastroenterologie. 2013;51(10):1177-83

Zeitz J, Huber M, Rogler G

[Serious course of a miliary tuberculosis in a 34-year-old patient with ulcerative colitis and HIV infection under concomitant therapy with infliximab].

Medizinische Klinik (Munich, Germany : 1983). 2010;105(4):314-8

Mayordomo L, Marenco JL, Gomez-Mateos J, Rejon E

Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment.

Scandinavian journal of rheumatology. 2002;31(1):44-5